NeuroMetrix, Inc. (NURO)
NASDAQ: NURO · Real-Time Price · USD
4.388
-0.033 (-0.74%)
Feb 21, 2025, 4:00 PM EST - Market closed

Company Description

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China.

Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.

The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons.

NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

NeuroMetrix, Inc.
NeuroMetrix logo
Country United States
Founded 1996
Industry Medical Devices
Sector Healthcare
Employees 26
CEO Shai Gozani

Contact Details

Address:
4B Gill Street
Woburn, Massachusetts 01801
United States
Phone 781 890 9989
Website neurometrix.com

Stock Details

Ticker Symbol NURO
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001289850
CUSIP Number 641255807
ISIN Number US6412558800
Employer ID 04-3308180
SIC Code 3841

Key Executives

Name Position
Dr. Shai N. Gozani M.D., Ph.D. Founder, Chairman, Chief Executive Officer, President and Secretary
Thomas T. Higgins Senior Vice President, Chief Financial Officer and Treasurer
Dr. Xuan Kong Ph.D. Chief Data Scientist
Susan M. Bell R.N. Senior Vice President of Population Health and Value Based Care

Latest SEC Filings

Date Type Title
Feb 14, 2025 DEFM14A Filing
Feb 13, 2025 SCHEDULE 13G/A Filing
Jan 30, 2025 PREM14A Filing
Jan 23, 2025 8-K Current Report
Dec 30, 2024 8-K Current Report
Dec 19, 2024 SCHEDULE 13D/A Filing
Dec 17, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Dec 17, 2024 8-K Current Report
Nov 5, 2024 10-Q Quarterly Report
Nov 5, 2024 8-K Current Report